JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

A Poor Prognostic ALK Phenotype: A Review of Molecular Markers of Poor Prognosis in ALK Rearranged Nonsmall Cell Lung Cancer

  • 0Department of Oncology, McMaster University, Hamilton, Ontario, Canada; Department of Medical Oncology, Juravinski Cancer Center, Hamilton, Ontario, Canada.
Clinical Lung Cancer +

|

November 22, 2024

|

November 22, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Patients with ALK-rearranged lung cancer can develop a poor prognostic phenotype due to specific genetic mutations. Understanding these molecular mechanisms, including variant 3 and TP53 mutations, is crucial for improving treatment outcomes.

Area Of Science

  • Oncology
  • Genetics
  • Molecular Biology

Background

  • Anaplastic lymphoma kinase (ALK) rearrangements are key drivers in a subset of nonsmall cell lung cancer (NSCLC).
  • Tyrosine kinase inhibitors (TKIs) offer significant clinical benefit for ALK-positive NSCLC patients.
  • A subset of patients exhibits early progression or death, termed the poor prognostic ALK phenotype.

Purpose Of The Study

  • To review and summarize molecular mechanisms underlying the poor prognostic ALK phenotype.
  • To focus on the roles of ALK variant 3 and TP53 mutations in TKI resistance.
  • To identify genomic factors contributing to early treatment failure in ALK-rearranged NSCLC.

Main Methods

  • A comprehensive scoping review of scientific databases (Ovid Medline, Embase, Cochrane).
  • Inclusion criteria focused on studies detailing molecular markers of poor prognosis, specifically TP53 mutations, variant 3 rearrangements, and TKI response.
  • Analysis of 108 selected studies from an initial screening of 4371.

Main Results

  • Variant 3 rearrangements and TP53 mutations are strongly associated with poor prognosis in ALK-positive NSCLC.
  • These mutations contribute to on-target resistance, chromosomal instability, and increased mutational burden.
  • Co-occurrence of variant 3 and TP53 mutations significantly worsens survival outcomes.
  • Aberrations in cell cycle regulators and signaling pathways also mediate early resistance.

Conclusions

  • The poor prognostic ALK phenotype is driven by a heterogeneous set of genomic factors.
  • A combination of genetic alterations, rather than a single signature, underlies early TKI resistance.
  • Development of a predictive genomic assay integrating multiple molecular markers is needed.

Keywords: